Article Menu
Need Help?
No Article Versions Notes Found
Cite
Figueiredo, A.; Atkins, H.; Mallick, R.; Kekre, N.; Kew, A.; McCurdy, A. Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma. Curr. Oncol. 2020, 27, 81-85. https://doi.org/10.3747/co.27.5385
Figueiredo A, Atkins H, Mallick R, Kekre N, Kew A, McCurdy A. Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma. Current Oncology. 2020; 27(2):81-85. https://doi.org/10.3747/co.27.5385
Chicago/Turabian StyleFigueiredo, A., H. Atkins, R. Mallick, N. Kekre, A. Kew, and A. McCurdy. 2020. "Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma" Current Oncology 27, no. 2: 81-85. https://doi.org/10.3747/co.27.5385
APA StyleFigueiredo, A., Atkins, H., Mallick, R., Kekre, N., Kew, A., & McCurdy, A. (2020). Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma. Current Oncology, 27(2), 81-85. https://doi.org/10.3747/co.27.5385
